Trials / Completed
CompletedNCT02132572
Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants
Retrospective Multi-centre, Post-marketing Study to Evaluate the Incidence and Aetiology of Reoperations With Allergan Natrelle® Breast Implants in Primary Augmentation (RANBI)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 201 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Retrospective multi-center, post-marketing study to evaluate the incidence and etiology of reoperations with Allergan Natrelle® Breast Implants in primary augmentation (RANBI)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | BIOCELL™ Textured 410 Implant | Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2014-05-07
- Last updated
- 2016-09-13
- Results posted
- 2016-09-13
Locations
5 sites across 5 countries: France, Germany, Israel, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02132572. Inclusion in this directory is not an endorsement.